Elementis Valuation

Is E3E undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of E3E when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: E3E (€1.7) is trading below our estimate of fair value (€5.12)

Significantly Below Fair Value: E3E is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for E3E?

Other financial metrics that can be useful for relative valuation.

E3E key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA8.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does E3E's PS Ratio compare to its peers?

The above table shows the PS ratio for E3E vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
ACT AlzChem Group
1x6.3%€576.0m
UZU Uzin Utz
0.5x4.2%€245.2m
WCH Wacker Chemie
0.7x4.8%€4.2b
2NF Syensqo
1.1x4.2%€7.9b
E3E Elementis
1.5x3.5%€844.8m

Price-To-Sales vs Peers: E3E is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (0.9x).


Price to Earnings Ratio vs Industry

How does E3E's PE Ratio compare vs other companies in the DE Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: E3E is expensive based on its Price-To-Sales Ratio (1.5x) compared to the European Chemicals industry average (1x).


Price to Sales Ratio vs Fair Ratio

What is E3E's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

E3E PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio0.5x

Price-To-Sales vs Fair Ratio: E3E is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst E3E forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.70
€2.13
+25.3%
10.0%€2.39€1.63n/a8
Oct ’25€1.93
€2.09
+8.5%
10.0%€2.35€1.61n/a8
Sep ’25€1.89
€2.04
+8.0%
9.8%€2.33€1.59n/a8
Aug ’25€1.87
€1.95
+4.2%
10.1%€2.19€1.51n/a8
Jul ’25€1.69
€1.91
+13.1%
8.9%€2.09€1.51n/a8
Jun ’25€1.77
€1.91
+8.0%
8.9%€2.09€1.51n/a8
May ’25€1.64
€1.93
+17.4%
8.7%€2.11€1.53n/a8
Apr ’25€1.61
€1.89
+17.6%
11.0%€2.12€1.49n/a8
Mar ’25€1.63
€1.78
+9.0%
10.6%€2.02€1.49n/a8
Feb ’25€1.65
€1.77
+7.0%
11.1%€2.01€1.49n/a8
Jan ’25€1.46
€1.58
+8.1%
12.2%€1.96€1.25n/a8
Dec ’24€1.35
€1.58
+16.9%
12.2%€1.96€1.25n/a8
Nov ’24€1.32
€1.59
+20.7%
13.5%€2.07€1.26n/a8
Oct ’24€1.37
€1.61
+17.2%
13.0%€2.05€1.28€1.939
Sep ’24€1.32
€1.57
+18.7%
12.4%€1.99€1.29€1.899
Aug ’24€1.27
€1.55
+21.8%
13.3%€1.98€1.28€1.879
Jul ’24€1.16
€1.56
+34.4%
11.2%€1.88€1.31€1.699
Jun ’24€1.23
€1.56
+26.8%
11.2%€1.88€1.31€1.779
May ’24€1.37
€1.54
+12.1%
11.4%€1.86€1.29€1.649
Apr ’24€1.33
€1.56
+17.4%
11.2%€1.91€1.33€1.619
Mar ’24€1.43
€1.56
+9.1%
13.0%€1.93€1.23€1.639
Feb ’24€1.40
€1.52
+8.7%
13.2%€1.90€1.17€1.659
Jan ’24€1.35
€1.52
+12.2%
13.5%€1.94€1.20€1.4610
Dec ’23€1.33
€1.51
+13.9%
14.9%€1.98€1.21€1.3510
Nov ’23€1.06
€1.60
+51.1%
13.7%€2.09€1.29€1.3210
Oct ’23€0.98
€1.66
+69.0%
12.2%€2.01€1.36€1.3710

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies